Mechanistic studies suggested that Lipo-MP-LPS efficacy is associated with its capacity to reshape the tumor micro-environment (TME) through the systemic activation of innate immune cells (notably M1 macrophages) and Th1-type adaptive immune responses (CD8/CD4 T-cells), and their recruitment at tumor site. The gene discussed is CD8A; the disease is neoplasm.